April 9, 2024
SEIKAGAKU CORPORATION(Securities Code: TSE 4548)

Seikagaku Announces an Academic Conference Presentation
on SI-6603 by Licensee Ferring Pharmaceuticals Inc.
This news release has been prepared with reference to the press release announced onApril 8, 2024 (local U.S. time) by Ferring Pharmaceuticals Inc., which has a license
agreement with Seikagaku. The original press release takes precedence.
The original press release is available at https://ferringusa.com/media/us-press-release/.
Seikagaku Corporation (Tokyo, Japan; "Seikagaku") announced today that FerringPharmaceuticals Inc. (Parsippany, NJ; "Ferring") gave an academic conference presentation on
three subjects concerning SI-6603 at the 26th Annual Meeting of the American Society ofInterventional Pain Physicians (ASIPP), held from April 4 to April 6, 2024 in Dallas, Texas (U.S.A.).
Seikagaku is currently developing SI-6603 (generic name: Condoliase) in the U.S. as aninvestigational therapy intended to treat radicular leg pain associated with lumbar disc herniation(LDH).
Presentation Summary A single intradiscal injection of SI-6603 demonstrated significantly greater improvement inleg pain vs. sham at Week 13 in a registrational Phase 3 clinical trial
 An integrated safety analysis showed SI-6603 was well tolerated and could offer a potential
treatment option for pain relief from LDH
 A real-world analysis of current treatments for LDH showed a gap in clinical management
and a need for new treatment options
For details, please refer to the press release on the following Ferring website.
https://ferringusa.com/media/us-press-release/
Reference Information<About SI-6603 >SI-6603, which contains condoliase as its active pharmaceutical ingredient, is aninvestigational product intended to treat radicular leg pain associated with lumbar disc herniation
via a single direct injection into the intervertebral disc. It has the potential benefit of not requiring
general anesthesia and being less invasive to patients than surgical treatment.
SI-6603 was developed by Seikagaku. Marketing approval in Japan for SI-6603 wasobtained from the Ministry of Health, Labour and Welfare in March 2018, and SI-6603 hasbeen sold as HERNICORE® 1.25 units for intradiscal injection through sales partner Kaken
Pharmaceutical Co., Ltd. (Tokyo, Japan) since August 1, 2018.
<About Ferring Pharmaceuticals>
Ferring Pharmaceuticals is a privately-owned, research-driven, specialty biopharmaceuticalgroup committed to building families and helping people live better lives. In the United States,Ferring is a leader in reproductive medicine and maternal health, and in areas ofgastroenterology and orthopaedics. Ferring is at the forefront of innovation in microbiomebased therapeutics and uro-oncology intravesical gene therapy.
For more information, https://www.ferringusa.com.
1

<Alliance with Ferring Pharmaceuticals>
Seikagaku and Ferring entered into a license agreement for SI-6603 in August 2016. Under
the license agreement, Ferring has acquired exclusive development and commercializationrights to SI-6603 worldwide, excluding Japan.
For details, please refer to the following press release.
Seikagaku Announces the Conclusion of an Exclusive Worldwide License Agreement(excluding Japan) for SI-6603, a Novel Treatment for Lumbar Disc Herniation
https://www.seikagaku.co.jp/en/news/news-2557126754645424970/main/0/link/20160829_e.pdf#######2